SGP.US SpyGlass Pharma, Inc.

Healthcare Biotechnology USA Stocks
31.43 USD
Close of Nov 18, 2026
17.06 39.92
Market cap
USD 1.05B
P/E
-
P/B
5.11x
ROE
-36.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SGP.US undervalued?

Graham number

The Graham number of SpyGlass Pharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SpyGlass Pharma, Inc. fundamental analysis

No fundamental analysis for SpyGlass Pharma, Inc. yet.

SpyGlass Pharma, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped…

Full company profile